Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial [with consumer summary]
Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, Van de Heyning CM, Esefeld K, von Korn P, Christle JW, Haykowsky MJ, Linke A, Wisloff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M, for the OptimEx-Clin Stud Group
JAMA 2021 Feb 9;325(6):542-551
clinical trial
7/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

IMPORTANCE: Endurance exercise is effective in improving peak oxygen consumption (peak VO2) in patients with heart failure with preserved ejection fraction (HFpEF). However, it remains unknown whether differing modes of exercise have different effects. OBJECTIVE: To determine whether high-intensity interval training, moderate continuous training, and guideline-based advice on physical activity have different effects on change in peak VO2 in patients with HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 5 sites (Berlin, Leipzig, and Munich, Germany; Antwerp, Belgium; and Trondheim, Norway) from July 2014 to September 2018. From 532 screened patients, 180 sedentary patients with chronic, stable HFpEF were enrolled. Outcomes were analyzed by core laboratories blinded to treatment groups; however, the patients and staff conducting the evaluations were not blinded. INTERVENTIONS: Patients were randomly assigned (1:1:1; n = 60 per group) to high-intensity interval training (3x38 minutes/week), moderate continuous training (5x40 minutes/week), or guideline control (1-time advice on physical activity according to guidelines) for 12 months (3 months in clinic followed by 9 months telemedically supervised home-based exercise). MAIN OUTCOMES AND MEASURES: Primary end point was change in peak VO2 after 3 months, with the minimal clinically important difference set at 2.5 mL/kg/min. Secondary end points included changes in metrics of cardiorespiratory fitness, diastolic function, and natriuretic peptides after 3 and 12 months. RESULTS: Among 180 patients who were randomized (mean age 70 years; 120 women (67%)), 166 (92%) and 154 (86%) completed evaluation at 3 and 12 months, respectively. Change in peak VO2 over 3 months for high-intensity interval training versus guideline control was 1.1 versus -0.6 mL/kg/min (difference 1.5 (95% CI 0.4 to 2.7)); for moderate continuous training versus guideline control, 1.6 versus -0.6 mL/kg/min (difference 2.0 (95% CI 0.9 to 3.1)); and for high-intensity interval training versus moderate continuous training, 1.1 versus 1.6 mL/kg/min (difference -0.4 (95% CI -1.4 to 0.6)). No comparisons were statistically significant after 12 months. There were no significant changes in diastolic function or natriuretic peptides. Acute coronary syndrome was recorded in 4 high-intensity interval training patients (7%), 3 moderate continuous training patients (5%), and 5 guideline control patients (8%). CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, there was no statistically significant difference in change in peak VO2 at 3 months between those assigned to high-intensity interval versus moderate continuous training, and neither group met the prespecified minimal clinically important difference compared with the guideline control. These findings do not support either high-intensity interval training or moderate continuous training compared with guideline-based physical activity for patients with HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02078947.

Full text (sometimes free) may be available at these link(s):      help